Targets › GNE
1 program from 1 company in 2 trials: 2 Phase 2; Neurology, Genitourinary.
Bifunctional enzyme that possesses both UDP-N-acetylglucosamine 2-epimerase and N-acetylmannosamine kinase activities, and serves as the initiator of the biosynthetic pathway leading to the production of N-acetylneuraminic acid (NeuAc), a critical precursor in the synthesis of sialic acids. By catalyzing this pivotal and rate-limiting step in sialic acid biosynthesis, this enzyme assumes a pivotal role in governing…. (UniProt, Q9Y223)
Open in Phaseline: the race on GNE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Leadiant Biosciences | ManNAc (N-acetyl-D-mannosamine monohydrate) Precursor for N-acetylneuraminic acid (Neu5Ac) biosynthesis; restores glycan sialylation i | GNE | Phase 2 | GNE Myopathy; Focal Segmental Glomerulosclerosis | – |
GNE Myopathy (1) Focal Segmental Glomerulosclerosis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.